2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 185

The Interferon Gene Signature Is Increased in Early DMARD Naive Rheumatoid Arthritis and Predicts a Poorer Response to Initial Therapy
Abstract Number: 791

The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Abstract Number: 1899

The Intestinal Involvement in Systemic Sclerosis Is Characterized By a Peculiar Gut Microbiota
Abstract Number: 2616

The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients
Abstract Number: 2786

The Janus Kinase Inhibitor Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
Abstract Number: 1898

The Lack of Association of Osteoporosis with Proton Pump Inhibitor in Scleroderma: A UK Single Centre Cohort Experience
Abstract Number: 654

The Level of B-Cell Active Cytokines and Soluble B-Cell Activating Factor/a Proliferation-Inducing Ligand Receptors in Patients with Primary Sjogren’s Syndrome
Abstract Number: 2855

The Long-Term Clinical Outcomes of Lupus Nephritis
Abstract Number: 747

The Long-Term Outcomes on Leflunomide Treatment in Patients with Lupus Nephritis: A Twelve-Year Follow-up Study
Abstract Number: 2540

The Longitudinal Impact of Biologic Use on Disability within a RA Registry
Abstract Number: 505

The Longitudinal Stability of the RA Biomarkers RF and ACPA in Classifying RA Subtypes over Extended Follow up
Abstract Number: 2046

The Low-Dose Intravenous Cyclophosphamide Euro-Lupus Regimen Does Not Impact the Ovarian Reserve of Lupus Patients, As Measured By Serum Anti-Mullerian Hormone Levels
Abstract Number: 2700

The Lymphatic System: A Gatekeeper for Migration of Pathogenic T-Cells Towards Synovial Joints and Entheses in Psoriasis
Abstract Number: 440

the Majority of Biologic Injectors Are Stored Under Suboptimal Conditions at Home
Abstract Number: 2145

The Modulation of Macrophage Polarization By SIRT1 Maybe New Target Therapy in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].